Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 30228778)

  • 1. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of adaptive immune effector therapies in solid tumors.
    Comoli P; Chabannon C; Koehl U; Lanza F; Urbano-Ispizua A; Hudecek M; Ruggeri A; Secondino S; Bonini C; Pedrazzoli P;
    Ann Oncol; 2019 Nov; 30(11):1740-1750. PubMed ID: 31435646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Liu Y; Zhang X; Han C; Wan G; Huang X; Ivan C; Jiang D; Rodriguez-Aguayo C; Lopez-Berestein G; Rao PH; Maru DM; Pahl A; He X; Sood AK; Ellis LM; Anderl J; Lu X
    Nature; 2015 Apr; 520(7549):697-701. PubMed ID: 25901683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune resilience in response to cancer therapy.
    Gicobi JK; Barham W; Dong H
    Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
    Bair SM; Mato A; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
    Moehler M; Göpfert K; Lenz HJ
    Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Targeting of the Colorectal Tumor Stroma.
    Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
    Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
    Cheung PF; Lutz M; Siveke JT
    Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
    Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
    World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Firing Up Cold Tumors.
    Cheng WC; Ho PC
    Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
    Welborn M; Duvic M
    Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
    Flaig TW
    J Natl Compr Canc Netw; 2018 May; 16(5S):636-638. PubMed ID: 29784744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
    Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
    Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
    Georganaki M; van Hooren L; Dimberg A
    Front Immunol; 2018; 9():3081. PubMed ID: 30627131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
    Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
    Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.
    Riley JM; Cross AW; Paulos CM; Rubinstein MP; Wrangle J; Camp ER
    Cancer; 2018 Apr; 124(8):1650-1659. PubMed ID: 29315503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of immune evasion in bladder cancer.
    Crispen PL; Kusmartsev S
    Cancer Immunol Immunother; 2020 Jan; 69(1):3-14. PubMed ID: 31811337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.